Humana (HUM) vs Illumina (ILMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Humana (HUM) has outperformed Illumina (ILMN) over the past year, gaining 71.7% versus a gain of 55.7%. Over five years, HUM leads with a -9.0% price change compared with -46.4% for ILMN. Humana is the larger company by market cap ($46.84 billion vs $29.15 billion), about 1.6 times the size.
On valuation, Humana trades at a lower forward P/E (21.1x vs 31.2x for Illumina). Humana pays a dividend yielding 0.91%, while Illumina does not currently pay one. Illumina converts more of its revenue into profit, with a net margin of 19.6% versus 0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUM | ILMN |
|---|---|---|
| Share price | $390.00 | $192.82 |
| Market cap | $46.84B | $29.15B |
| 1-day change | +2.63% | -3.90% |
| YTD return | +52.27% | +47.01% |
| 1-year return | +71.73% | +55.69% |
| 5-year return | -8.98% | -46.40% |
| P/E ratio (TTM) | 38.05 | 33.19 |
| Forward P/E | 21.06 | 31.19 |
| EPS (TTM) | $10.25 | $5.81 |
| Dividend yield | 0.91% | 0.00% |
| Annual dividend | $3.54 | $0.00 |
| Revenue (latest FY) | $129.66B | $4.34B |
| Revenue growth (YoY) | +10.11% | -0.66% |
| Net income (latest FY) | $1.19B | $850.00M |
| Gross margin | — | 66.08% |
| Operating margin | 2.09% | 18.58% |
| Net margin | 0.92% | 19.57% |
| 52-week high | $462.87 | $309.35 |
| 52-week low | $163.11 | $112.65 |
| Distance from 52-week high | -15.74% | -37.67% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +30.98% | +35.59% |
| Average volume | 1.46M | 2.82M |
| Shares outstanding | 120.10M | 151.20M |
| Employees | 67,060 | 8,600 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUM has outperformed ILMN by 16.0 percentage points over the past year.
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus 0.9 cents for Humana.
- Humana grew revenue faster in its latest fiscal year (+10.11% vs -0.66%).
About Humana
HUM stock →Humana Inc. provides medical and specialty insurance products in the United States.
Health Care · Medical Specialities · 67,060 employees
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Health Care · Medical Specialities · 8,600 employees
HUM vs ILMN FAQ
Which is bigger, Humana or Illumina?
Humana (HUM) is larger, with a market capitalization of $46.84B compared with $29.15B for Illumina (ILMN).
Which stock has performed better over the past year, HUM or ILMN?
HUM returned +71.73% over the past 12 months, compared with +55.69% for ILMN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HUM or ILMN?
ILMN has the lower trailing P/E at 33.2, versus 38.0 for HUM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Humana or Illumina?
Humana pays a dividend yielding 0.91%, while Illumina does not currently pay a regular dividend.
Are Humana and Illumina in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.